Amputation and gangrene associated with SGLT2 inhibitors: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database
Journal of Endocrinological Investigation · 08.01.2026 · 49 (6) · 1381-1390
DOI: 10.1007/s40618-026-02809-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Endocrinological Investigation, online erschienen am 08.01.2026. Verfasst von Alyaa M Ajabnoor. Beteiligte Einrichtung: Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, P.O. BOX 80324, Jeddah, 21589, Saudi Arabia. ammajabnour@kau.edu.sa. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Amputation, Surgical, Adverse Drug Reaction Reporting Systems, Gangrene. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Sodium-glucose co-transporter-2 (SGLT2) inhibitors are widely prescribed to diabetic patients for their cardiorenal benefits. However, concerns over adverse events—specifically amputation risk and gangrene—have risen in recent years. This study aimed to describe the frequency and severity of these events in relation to SGLT2 inhibitor use, using the U.S. FDA Adverse Event Reporting System (FAERS).
Methods
OpenVigil 2.1 was used to extract safety reports submitted to FAERS from 2003 Q4 to 2024 Q4. Amputation and gangrene events linked to SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) were identified and compared to other drugs. Reporting odds ratios (RORs) were calculated.
Results
A total of 3,540 adverse event reports were identified: 2,128 for canagliflozin, 361 for dapagliflozin, 1,049 for empagliflozin, and 2 for ertugliflozin. Canagliflozin was strongly associated with toe amputation (ROR = 635.6; 95%CI: 566.7–712.1), foot amputation (ROR = 201.8; 95%CI: 174.3–233.7), and Fournier’s gangrene (ROR = 117.5; 95%CI: 100.0–138.0). Empagliflozin was linked with Fournier’s gangrene (ROR = 565.2; 95%CI: 525.3–608.2) and toe amputation (ROR = 21.2; 95%CI: 17.6–25.6). Dapagliflozin showed weaker signals; ertugliflozin had minimal data.
Conclusion
Toe amputation and Fournier’s gangrene were most reported with canagliflozin and empagliflozin, reinforcing prior safety concerns and the need for monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, P.O. BOX 80324, Jeddah, 21589, Saudi Arabia. ammajabnour@kau.edu.sa.
- Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK. ammajabnour@kau.edu.sa.
Zitieren
APA
Ajabnoor, A. M. (2026). Amputation and gangrene associated with SGLT2 inhibitors: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Journal of Endocrinological Investigation, 49(6), 1381-1390. https://doi.org/10.1007/s40618-026-02809-3
Vancouver
Ajabnoor AM. Amputation and gangrene associated with SGLT2 inhibitors: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Journal of Endocrinological Investigation. 2026;49(6):1381-1390. doi:10.1007/s40618-026-02809-3
BibTeX
@article{Ajabnoor2026,
author = {Ajabnoor, Alyaa M},
title = {Amputation and gangrene associated with SGLT2 inhibitors: pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database},
journal = {Journal of Endocrinological Investigation},
year = {2026},
volume = {49},
number = {6},
pages = {1381--1390},
doi = {10.1007/s40618-026-02809-3}
}
EUVIMED